埃伦贝斯塔特和化合物89在非人类灵长类动物中服用亚慢性剂量时,可能抑制BACE1,但不能抑制BACE2
Sarah K Tschirner1,2, Andree Schmidt1,2,3, Mana Ito4
1German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Proteomics
|November 28, 2025
概括
阿尔茨海默病药物向BACE1,但BACE2的联合抑制可能导致认知问题. 在CSF中的VCAM-1显示为BACE2活性在药物开发中的生物标志物具有前途.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- β-分泌酶1 (BACE1) 是阿尔茨海默病 (AD) 药物开发的关键标,催化了粉样β (Aβ) 生成.
- 对BACE1抑制剂的临床试验因认知副作用而面临挫折,可能与BACE1同源BACE2.的非目标抑制有关.
- VCAM-1是BACE2活动的拟议脑脊液 (CSF) 生物标志物,但其体内验证缺乏.
研究的目的:
- 在体内评估VCAM-1作为BACE2标参与的药理学生物标志物.
- 评估新型和现有的BACE抑制剂的体内BACE1和BACE2抑制特征.
- 研究BACE1抑制剂试验中观察到的认知副作用背后的机制.
主要方法:
- 在非人类灵长类动物中使用BACE抑制剂 (化合物89,elenbecestat,verubecestat) 的亚慢性剂量.
- 脑脊液 (CSF) 药物保护学分析以测量基质水平.
- 量化BACE1和BACE2基质,包括VCAM-1,以评估目标接触.
主要成果:
- 化合物89和elenbecestat选择性抑制了BACE1,由减少的BACE1基质证明而没有影响VCAM-1水平.
- 作为双重BACE1/BACE2抑制剂的Verubecestat可以降低BACE1和BACE2基质 (VCAM-1).
- 这些发现支持VCAM-1作为BACE2抑制的生物标志物的实用性.
结论:
- VCAM-1 是一个合适的药理动力学生物标志物,用于评估BACE2在CSF中的目标参与.
- 选择性BACE1抑制可以在不影响BACE2的情况下实现,从而可能减轻认知副作用.
- 了解BACE1/BACE2选择性对于开发更安全,更有效的阿尔茨海默病治疗方法至关重要.
相关概念视频
01:22Dose-Response Relationship: Potency and Efficacy
6.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.3K
01:30Enzyme Inhibition
91.3K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
91.3K
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.5K